Full spectrum anti-dengue antibody
First Claim
1. An antibody agent comprising at least one antibody, which at least one antibody comprises two heavy chains and two light chains, wherein:
- the heavy chain CDRs are identical to reference CDRs found between residues 27 and 33, residues 53 and 58, and residues 100 and 106 of SEQ ID NO;
29 except that at least one of the heavy chain CDRs differs by a single amino acid substitution relative to its reference CDR; and
the light chain CDRs are identical to reference CDRs found between residues 24 and 38, residues 54 and 60, and residues 93 and 101 of SEQ ID NO;
30, or at least one of the light chain CDRs differs by a single amino acid substitution relative to its reference CDR, wherein the antibody agent;
(i) competes with reference antibody 4E5A for binding to Dengue Virus;
or(ii) binds to an epitope that is or comprises an amino acid sequence within;
SEQ ID NO;
17 (EDIII-DV1), SEQ ID NO;
18 (EDIII-DV2), SEQ ID NO.;
19 (EDIIIDV3), SEQ ID NO;
20 (EDIII-DV4), or combinations thereof.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
34 Citations
26 Claims
-
1. An antibody agent comprising at least one antibody, which at least one antibody comprises two heavy chains and two light chains, wherein:
-
the heavy chain CDRs are identical to reference CDRs found between residues 27 and 33, residues 53 and 58, and residues 100 and 106 of SEQ ID NO;
29 except that at least one of the heavy chain CDRs differs by a single amino acid substitution relative to its reference CDR; andthe light chain CDRs are identical to reference CDRs found between residues 24 and 38, residues 54 and 60, and residues 93 and 101 of SEQ ID NO;
30, or at least one of the light chain CDRs differs by a single amino acid substitution relative to its reference CDR, wherein the antibody agent;(i) competes with reference antibody 4E5A for binding to Dengue Virus;
or(ii) binds to an epitope that is or comprises an amino acid sequence within;
SEQ ID NO;
17 (EDIII-DV1), SEQ ID NO;
18 (EDIII-DV2), SEQ ID NO.;
19 (EDIIIDV3), SEQ ID NO;
20 (EDIII-DV4), or combinations thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26)
-
-
18. An antibody agent comprising an antigen-binding fragment of an antibody that comprises two heavy chains and two light chains, wherein:
-
the heavy chain CDRs are identical to reference CDRs found between residues 27 and 33, residues 53 and 58, and residues 100 and 106 of SEQ ID NO;
29 except that at least one of the heavy chain CDRs differs by a single amino acid substitution relative to its reference CDR; andthe light chain CDRs are identical to reference CDRs found between residues 24 and 38, residues 54 and 60, and residues 93 and 101 of SEQ ID NO;
30, or at least one of the light chain CDRs differs by a single amino acid substitution relative to its reference CDR,wherein; the antigen-binding fragment comprises the heavy chain CDRs and the light chain CDRs; and
the antibody agent;(i) competes with reference antibody 4E5A for binding to Dengue Virus;
or(ii) binds to an epitope that is or comprises an amino acid sequence within;
SEQ ID NO;
17 (EDIII-DV1), SEQ ID NO;
18 (EDIII-DV2), SEQ ID NO.;
19 (EDIIIDV3), SEQ ID NO;
20 (EDIII-DV4), or combinations thereof.
-
Specification